Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 5, 2012
Reporting Period: The filing references financial results for the three and nine-month periods ended September 30, 2012, and a patent event occurring on November 5, 2012.
Key Financial Metrics
This Form 8-K serves as a notification of events and does not contain specific financial data tables within the body text. It references a press release (Exhibit 99.1) for detailed results.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide clear values for these metrics. Specific figures are contained in the referenced press release dated November 7, 2012.
Material Changes and Events
- Financial Results Notification: The Company issued a press release on November 7, 2012, detailing financial results for the three and nine months ended September 30, 2012.
- Intellectual Property: On November 5, 2012, the US Patent and Trademark Office issued two patents covering the Company's product Trokendi XR.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, or risk factors. It directs readers to the attached press releases (Exhibits 99.1 and 99.2) for further details on financial performance and patent approvals.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 7, 2012) for specific revenue, net loss, and cash position figures for the period ended September 30, 2012.
- Review Exhibit 99.2 (Press Release dated November 5, 2012) for details on the scope and implications of the two new patents for Trokendi XR.
- Verify the impact of the patent issuance on the Company's competitive landscape and potential revenue protection.